Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.41 |
| ▸ | F11 | P03951 | 3/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2774399 | 0.93 | GAA (0.44) | LCKFYNALDH1A1STING1F11 | |
| SCHEMBL2806797 | 0.86 | GAA (0.48) | ALDH1A1LMNAHTTSTING1IMPDH2 | |
| SCHEMBL8902619 | 0.81 | ALDH1A1 (0.50) | LCKFYNALDH1A1STING1F11 | |
| SCHEMBL1766160 | 0.81 | LCK (0.60) | LCKFYNALDH1A1LMNAMAPK1 | |
| SCHEMBL2771853 | 0.81 | CHEK1 (0.49) | LCKFYNALDH1A1STING1F11 | |
| SCHEMBL5470003 | 0.81 | ALDH1A1 (0.46) | LCKFYNALDH1A1LMNAMAPK1 | |
| SCHEMBL8300964 | 0.79 | TRPV4 (0.48) | KDM4E | |
| SCHEMBL18700941 | 0.79 | HTT (0.55) | LCKFYNALDH1A1LMNAMAPK1 | |
| SCHEMBL286978 | 0.79 | KDM4E (0.50) | ALDH1A1IMPDH2KDM4EUSP2 | |
| SCHEMBL25851502 | 0.77 | CHEK1 (0.46) | LCKFYNALDH1A1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2193125-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-01-11 | — | — | EP | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-2193125-A2 | OXADIAZOLE DERIVATIVES | Merck Serono S.A. (CH) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009043889-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240658-A1 | Oxadiazole Derivatives | OXA1L, RO60, NQO2 | LCK 912/4885FYN 1142/4885ALDH1A1 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.